HealthCore and Novo Nordisk to collaborate on long-term pragmatic clinical trial of Ozempic in Type 2 diabetic patients

Written by The Evidence Base
Diabetes Industry Updates Medical devices, pharmaceuticals and vaccines Methodology News Real-world evidence

HealthCore Inc. (DE, USA) and Nordisk Inc. (Bagsværd, Denmark) have plans for a randomized pragmatic clinical trial of Ozempic (semaglutide) for Type 2 diabetic patients to analyze its long-term effectiveness and real-world benefits. HealthCore Inc. (DE, USA), the outcomes research subsidiary of Anthem Inc. (IN, USA), and Novo Nordisk Inc. (Bagsværd, Denmark), have announced they are collaborating to launch a first of its kind pragmatic study into Ozempic (semaglutide), comparing it to numerous other available diabetic drugs, in a clinal trial for Type 2 diabetes.  Novo Nordisk currently manufactures the once weekly GLP-1 receptor agonist Ozempic. GLP-1 receptor agonists are...

To view this content, please register now for access

It's completely free